TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18316236
Drug: Involuntary movements
Normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involuntary movements not concurrent to speech
Study: 16702822
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (20 mg/day)
Study: 8127929
Drug: Moclobemide (300‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300‐600 mg/d)
Study: 8127929
Drug: Maprotiline (75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (75‐150 mg/d)
Study: 28985255
Drug: Haloperidol 1
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1 mg orally twice-daily (maximum of 14 doses)
Study: 23510450
Drug: 17 G/
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17 G/ 35 mm (standard) needle
Study: 23510450
Drug: 20 G/
Normalized name: calcium gluconate 20 g/1000 mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G/ 35 mm (thin) needle
Study: 18602599
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (specific molecules not detailed)
Study: 18602599
Drug: Cytotoxic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic chemotherapy (not explicitly detailed)
Study: 16736333
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (intravenous for 2 days, followed by oral for 10 days)
Study: 11775892
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg-20 mg, three times daily before labor, orally every 6 hours during labor)
Study: 7036292
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with 5-fluorouracil (10 mg/kg/day) and BCNU (40 mg/m2/day) for 5 days, administered eight times in 6‐8 week intervals.
Study: 7036292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chemotherapy).
Study: 29705869
Drug: Suvorexant 100
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 100 mg
Study: 27253658
Drug: Suvorexant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (all doses)
Study: 26809022
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy (esomeprazole 20 mg and amoxicillin 1000 mg twice daily for 14 days with the addition of clarithromycin 500 mg and tinidazole 500 mg twice daily for the final 7 days)
Study: 7299385
Drug: Caffeine 10
Normalized name: caffeine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 10 mg/kg
Study: 21503180
Drug: Caffeine 15
Normalized name: caffeine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 15 mg/kg
Study: 11026396
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of glucose
Study: 1587426
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (three times weekly for 1 month)
Study: 27588932
Drug: 20 units
Normalized name: Omnipod GO 20 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 units of oxytocin diluted in 500 mL of lactated Ringer solution
Study: 27588932
Drug: 30 units
Normalized name: Omnipod GO 30 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 units of oxytocin diluted in 500 mL of lactated Ringer solution
Study: 27588932
Drug: 40 units
Normalized name: Omnipod GO 40 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 units of oxytocin diluted in 500 mL of lactated Ringer solution
Study: 15451899
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (1.6 mg)
Study: 15451899
Drug: Carrier solution
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier solution (control)
Study: 11253562
Drug: Budipine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine (3 x 20 mg/d)
Study: 11253562
Drug: Amantadine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (3 x 100 mg/d)
Study: 8173712
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (intravenous tissue plasminogen activator in 561 patients, urokinase in 102 patients, combination of tissue plasminogen activator and urokinase in 147 patients)
Study: 2946815
Drug: Streptozotocin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses
Study: 31365489
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate solution infusion
Study: 31365489
Drug: Infusions in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions in normovolemic state
Study: 18221410
Drug: lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 400 mg o.d.
Study: 8527613
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg b.d.
Study: 18221410
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg t.d.s.
Study: 12615747
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (general)
Study: 8249554
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) morphine
Study: 24955739
Drug: Oral valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral valproic acid (VPA) 500mg once daily for 1 year
Study: 12695832
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s without flush (Group 1)
Study: 12695832
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s with a 30-ml flush (Group 2)
Study: 12695832
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s without flush (Group 3)
Study: 12695832
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s with a 30-ml flush (Group 4)
Study: 12695832
Drug: Higher injection
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher injection rate protocols (Groups 1 and 2)
Study: 1661447
Drug: Standard Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Heparin (SH)
Study: 30012389
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (n=47)
Study: 27358159
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of hyaluronic acid (HA)
Study: 27358159
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of oxygen ozone (O2O3)
Study: 27358159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyaluronic acid (HA) and oxygen ozone (O2O3)
Study: 24776953
Drug: Alternative monotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative monotherapy with a second AED (Group A)
Study: 24776953
Drug: Add-on treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on treatment with a second AED (Group B)
Study: 22570370
Drug: Adherence and
Normalized name: dressing,low adherence and wound contact materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence and Intensification of Medications intervention
Study: 17456583
Drug: Oseltamivir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (all doses)
Study: 12487226
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg for ages 6 to < 14 years; 10 mg for > 14 years)
Study: 9660559
Drug: Dynamic k-space
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic k-space filling with bolus chase 3D MRDSA using a 25-ml gadolinium dose and a multiple-phase 3D fast gradient-echo sequence.
Study: 2539648
Drug: IE (ifosfamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IE (ifosfamide, 1.5 g/m2, days 1 through 5; etoposide, 120 mg/m2, days 3 through 5)
Study: 2539648
Drug: CAV (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV (cyclophosphamide, 600 mg/m2, days 1 and 2; doxorubicin, 50 mg/m2, day 1; vincristine, 2 mg, day 1)
Study: 2539648
Drug: PE (cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE (cisplatin, 90 mg/m2, day 1; etoposide, 150 mg/m2, days 3 through 5)
Study: 2539648
Drug: IAV (ifosfamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAV (ifosfamide, 2 g/m2, days 1 to 5; doxorubicin, 25 mg/m2, days 1 and 2; vincristine, 2 mg, day 1)
Study: 2539648
Drug: PE or
Normalized name: M-End PE Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE or JE (carboplatin, 300 mg/m2, day 1; etoposide, 120 mg/m2, days 1 to 3)
Study: 362519
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 1 g twice daily for one day
Study: 362519
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50 mg/kg
Study: 362519
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage regime (1 g twice daily)
Study: 30825563
Drug: Traditional debridement
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional debridement therapy
Study: 28093383
Drug: Semi-standardised individual
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-standardised individual acupuncture inspired by Traditional Chinese Medicine
Study: 11181985
Drug: Active NCPAP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active NCPAP therapy
Study: 11181985
Drug: Sub-therapeutic NCPAP
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-therapeutic NCPAP therapy
Study: 7851269
Drug: Diabetic subjects
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic subjects (mean glomerular filtration rate 216 ml/min)
Study: 7851269
Drug: Diabetic subjects
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic subjects (corrected for body size, mean glomerular filtration rate 165.6 ml/min per 1.73 m2)
Study: 7851269
Drug: Diabetic subjects
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic subjects (albumin excretion median 61 mg/day)
Study: 3072940
Drug: HR-6 solutions
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR-6 solutions containing adenosine triphosphate (0.5 or 5 mg/ml)
Study: 29505742
Drug: Delayed rotator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed rotator cuff repair after 6 months of nonoperative treatment (Group 2, n = 34)
Study: 20736152
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono)
Study: 2888302
Drug: Carvedilol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol, 50 mg
Study: 2888302
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg
Study: 2888302
Drug: Carvedilol, 25
Normalized name: Carvedilol, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol, 25 mg
Study: 23558890
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg daily
Study: 16620590
Drug: Intramuscular revaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular revaccination (10 microg per dose)
Study: 16620590
Drug: Intradermal revaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal revaccination (2 microg per dose)
Study: 16310902
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose (5 microg) for those who lost seroprotection
Study: 10907947
Drug: 5-fluorouracil (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o. every two weeks)
Study: 10907947
Drug: Leucovorin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (20 mg/m2 i.v.), 5-fluorouracil and levamisole
Study: 9362435
Drug: Clodronate, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate, 300 mg/day intravenously (i.v.)
Study: 9362435
Drug: Oral clodronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate, 1600-3200 mg/day
Study: 9362435
Drug: Alendronate, 5
Normalized name: Alendronate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 5 mg i.v. as a single infusion
Study: 9362435
Drug: Alendronate, 40
Normalized name: Alendronate, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 40 mg orally/day
Study: 27725911
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with docetaxel (DOC) plus nedaplatin (NDP) followed by IMRT concurrent with weekly NDP
Study: 12947431
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of guar gum (3.6 g galactomannan)
Study: 12947431
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of fructose
Study: 12947431
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of guar gum + 5 g of fructose
Study: 12947431
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 g of available carbohydrate from maltodextrin and white bread)
Study: 9249631
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole (95% collagen and 5% metronidazole device) combined with mechanical treatment
Study: 9249631
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment alone
Study: 3828955
Drug: L‐phenylalanine mustard
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐phenylalanine mustard (L‐PAM) and 5‐fluorouracil (5‐FU) with tamoxifen
Study: 3828955
Drug: L‐phenylalanine mustard
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐phenylalanine mustard (L‐PAM) and 5‐fluorouracil (5‐FU) without tamoxifen
Study: 23752849
Drug: Intraoperative ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ozone and postoperative millimeter wave therapy
Study: 12954574
Drug: 5‐fluorouracil [450
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil [450 mg/m(2) intravenous (i.v.) bolus on days 1‐5] and levamisole (150 mg orally for 3 days, every 14 days for 6 months)
Study: 12954574
Drug: 6‐S‐leucovorin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐S‐leucovorin (100 mg/m(2) i.v. bolus on days 1‐5) followed by 5‐fluorouracil (370 mg/m(2) i.v. bolus on days 1‐5), plus levamisole (as arm A), every 4 weeks for six cycles
Study: 1347757
Drug: Lovastatin (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20‐80 mg daily)
Study: 2863220
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg three times a day)
Study: 30035578
Drug: Alcohol targeting
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol targeting a blood alcohol concentration (BAC) of .08 g%
Study: 21153822
Drug: Zibotentan 10
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 10 mg plus pemetrexed 500 mg/m²
Study: 21153822
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus pemetrexed 500 mg/m²
Study: 8227863
Drug: Aqueous beclomethasone
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous beclomethasone dipropionate (168 micrograms twice daily)
Study: 8227863
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (220 micrograms twice daily)
Study: 3524050
Drug: Live cold-adapted
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live cold-adapted recombinant bivalent vaccine of influenza type A
Study: 14566214
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patches
Study: 12584575
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine patch
Study: 28148501
Drug: Enalapril-folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-folic acid (10 mg enalapril and 0.8 mg folic acid)
Study: 26254941
Drug: Self-Regulation Treatment
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Regulation Treatment Group (n = 136)
Study: 26254941
Drug: Self-Efficacy Treatment
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Efficacy Treatment Group (n = 138)
Study: 21088912
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary for 7 days
Study: 17217572
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Ca/d
Study: 8154971
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous ganciclovir for 3 weeks (group 2, n = 24)
Study: 8154971
Drug: Seven doses
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven doses of intravenous immunoglobulin for 6-week periods (group 1, n = 27)
Study: 3042356
Drug: urapidil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil (60 to 120 mg/day)
Study: 26298795
Drug: Nightly dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly dosing with 10 mg zolpidem (QHS-10)
Study: 26298795
Drug: Nightly dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly dosing with 5 mg zolpidem (QHS-5)
Study: 26298795
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing with 10 mg zolpidem (IDS-10)
Study: 26298795
Drug: Partial reinforcement
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial reinforcement dosing with 10 mg zolpidem (PRS-10)
Study: 23246610
Drug: Treatment indicated
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment indicated for schizophrenia (specific treatments not detailed in the abstract)
Study: 16930215
Drug: Post-discontinuation of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation of alcohol at 0.1% BAL
Study: 12966595
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 300 mg twice daily
Study: 10894865
Drug: Cisplatin/continuous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/continuous infusion doxorubicin (regimen B)
Study: 9410281
Drug: Bronchodilator inhalation
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator inhalation (0.2 mg fenoterol)
Study: 9410281
Drug: Patients unresponsive
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients unresponsive to beta‐agonist (delta FEVI <= 15%)
Study: 1589588
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg RS 86 (cholinergic agonist)
Study: 27856202
Drug: Joint National
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint National Committee (JNC) 7 compliant treatment with intensive BP goals (<120/80 mm Hg)
Study: 16386539
Drug: Cyclosporine (G-1)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (G-1)
Study: 16386539
Drug: Tacrolimus (G-2)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (G-2)
Study: 7751412
Drug: Indapamide 1.25
Normalized name: indapamide 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.25 mg/day
Study: 2647556
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (330 mg 3 times daily)
Study: 2647556
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (75 mg 3 times daily)
Study: 26411993
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients
Study: 29525823
Drug: Feracrylum 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feracrylum 1% solution (FS)
Study: 24786017
Drug: Sildenafil fine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil fine granule 50 mg
Study: 24786017
Drug: Sildenafil tablet
Normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil tablet 50 mg
Study: 18333865
Drug: Cotrimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (960 mg b.i.d.; 160 mg trimethoprim and 800 mg sulfamethoxazole)
Study: 18333865
Drug: Tenofovir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir (300 mg q.d.)